P-132Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine+placebo versus gemcitabine+evofosfamide and identifies candidate targets. (20th June 2018)

Record Type:: Journal Article
Title:: P-132Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine+placebo versus gemcitabine+evofosfamide and identifies candidate targets. (20th June 2018)
Main Title:: P-132Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine+placebo versus gemcitabine+evofosfamide and identifies candidate targets
Authors:: Domenyuk, V
Liu, X
Magee, D
Gatalica, Z
Stark, A
Kennedy, P
Rosenow, M
Barker, A
Berry, D
Poste, G
Halbert, D
Hart, C
Famulok, M
Mayer, G
Korn, M
Miglarese, M
Spetzler, D
Abstract:
Is Part Of:: Annals of oncology. Volume 29(2018)Supplement 5
Journal:: Annals of oncology
Issue:: Volume 29(2018)Supplement 5
Issue Display:: Volume 29, Issue 5 (2018)
Year:: 2018
Volume:: 29
Issue:: 5
Issue Sort Value:: 2018-0029-0005-0000
Page Start:
Page End:
Publication Date:: 2018-06-20
Subjects:: Oncology -- Periodicals
616.992
Journal URLs:: https://www.journals.elsevier.com/annals-of-oncology ↗
http://ukcatalogue.oup.com/ ↗
DOI:: 10.1093/annonc/mdy151.131 ↗
Languages:: English
ISSNs:: 0923-7534
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 1043.320000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 12264.xml